ml141 (cdc42/rac1 gtpase inhibitor (Millipore)
Structured Review

Ml141 (Cdc42/Rac1 Gtpase Inhibitor, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ml141 (cdc42/rac1 gtpase inhibitor/product/Millipore
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinson’s disease degeneration"
Article Title: Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinson’s disease degeneration
Journal: bioRxiv
doi: 10.1101/2024.07.04.602092
Figure Legend Snippet: A. CD16/32 accumulates at the leading front of motile microglia. Top panel shows maximum intensity projection of a BV2 cell marked with CD16/32 and DAPI. Leading lamellas (left pole) and the uropod (opposite pole) indicate its direction. Bottom panel shows a 0.5 mm optical plane represented in a scale of 16 colors. Scale on the bottom (white represents the highest value and black the lowest). Leading front lamellas (1) and uropod (2) are indicated. B. Illustration of characteristic motile microglial cell showing essential cytoskeletal elements (Modified from Roig-Martinez et al., 2019) . C. Plot of relative fluorescence of motile microglia measured (white broken line) from image on the left. Note the higher fluorescence at the leading front (1) and a smaller peak at the uropod (2). All images scale bars equal 10 μm. D. Representative image of a BV2 microglial cell expressing high density of Cdc42 (red) in a F-actin-rich protrusion. The nucleus was counterstained with DAPI (blue). Scale bar: 3 μm. E. Plot profile of relative fluorescence displays high expression of Cdc42 corresponding with high fluorescence of F-actin at the protruding edge (2) compared with the nucleus (1). F. Confocal image of microglial cell establishing a phagocytic cup around a dopaminergic cell (1). The PC12 DA cell is marked with dopaminergic neuronal marker, TH (green), and the microglial cell is stained by F-actin (magenta). (2) Diagram of the engulfing process depicted in 1. (3) Image of F-actin fluorescence intensity of the engulfing microglia seen in 1. Note the higher intensity is displayed at the borders of the phagocytic cup. (4) higher magnification of the phagocytic cup to visualize the characteristic accumulations of F-actin. Scale bar: 10 mm. (5) 3D reconstruction of the phagocytic event displaying the microglia arranging the F-actin rich phagocytic cup around a dopaminergic cell (yellow arrowhead). G. Increasing concentrations of ML141 were safe for BV2 cell viability. MTT cell viability assay for BV2 microglial cells submitted to increasing concentrations of ML141 was performed to test their safety: 500 μg of H 2 O 2 resulted in approximately 50% decrease of the cell viability. But no significant decrease was appreciated after the administration of ML141 or vehicle (*** p˂0.001 H 2 O 2 significant against every other treatment). H. Quantification of the number of PC12 DA cells at 60 min. of interaction with BV2 microglia. BV2 were treated either before or after activation with Cdc42 inhibitor ML141. The proinflammatory-mediated elimination of DA cells was prevented when BV2 cells were incubated with ML141. (Pre-activation inhibition ** p˂0.01 IFN-γ + LPS vs. ML141/IFN-γ +LPS and ML141. Post-activation inhibition $$$ p˂0.001 IFN-γ + LPS vs. every condition and **** p˂0.0001 control vs. IFN-γ + LPS).
Techniques Used: Modification, Fluorescence, Expressing, Marker, Staining, Viability Assay, Activation Assay, Incubation, Inhibition, Control
Figure Legend Snippet: A. Diagram of the procedure used for the CD16/32 passive immunotherapy. Neuropathological histology was performed in the SNpc (red square). B. Representative confocal images showing the SNpc labeled with TH and counterstained with DAPI. Depletion of DA neurons can be appreciated in MPTP-treated animals. However, a protective effect can be seen in mice treated with CD16/32 neutralizing monoclonal antibodies (aCD16/32) (Scale bar: 30 mm). C. Quantification of the DA neurons in the SNpc demonstrating a significant decrease in the MPTP group which is prevented by the administration of CD16/32 (*** p˂0.001 MPTP vs. every treatment except MPTP + Isotype, ### p˂0.001 MPTP + Isotype vs. every treatment except MPTP). D. 3D reconstruction of representative microglial cells expressing Iba-1 in different treatments of the experiment (Scale bar: 10 µm). C. Quantification of the area of Iba-1 in the SNpc, indicating variation of microglial size when the animals were intoxicated with MPTP. F. Diagram of the procedure used for Cdc42 inhibition. G. Representative confocal images of histological analysis. Upper panel: Representative images of TH positive neurons of the SNpc in every treatment (scale bar: 30 µm). Lower panel: 3D reconstructions illustrating morphology and changes of size in microglial cells expressing Iba-1 (scale bar: 10 µm). H. Quantification of TH positive neurons indicating a significant decrease in the MPTP group and prevention by the previous administration of Cdc42 inhibitor ML141 (** p <0.01 with respect to saline). I. Quantification of the Iba-1 expressing area, which represents changes in microglial size. Microglial activation is present in the MPTP group evidenced by the increased area of Iba-1, which is decreased in the animals intoxicated with MPTP but previously treated with ML141 (*** p<0.001 with respect to controls, $$ p<0.01 with respect to ML141).
Techniques Used: Labeling, Expressing, Inhibition, Saline, Activation Assay

